论文部分内容阅读
[目的]探讨NM23-H1、CD44v6在无淋巴结转移的非小细胞肺癌(N0 NSCLC)中的表达及其临床意义。[方法]应用免疫组织化学的方法检测60例手术后病理证实N0NSCLC组织NM23-H1、CD44v6的表达,分析其表达与患者术后5年预后的关系。[结果]NM23-H1及CD44v6的表达在鳞癌与腺癌间差异均无显著性意义;NM23-H1阳性表达与患者5年预后呈正相关(r=0.887),CD44v6阳性表达与患者5年预后呈负相关(r=-0.784)。[结论]癌组织NM23-H1、CD44v6的表达可作为评估N0 NSCLC患者预后的指标。
[Objective] To investigate the expression of NM23-H1 and CD44v6 in non-small cell lung cancer (N0 NSCLC) without lymph node metastasis and its clinical significance. [Methods] Immunohistochemistry was used to detect the expression of NM23-H1 and CD44v6 in 60 NSCLC patients after operation. The relationship between the expression of NM23-H1 and CD44v6 in 5-year postoperative prognosis was analyzed. [Results] There was no significant difference in the expression of NM23-H1 and CD44v6 between squamous cell carcinoma and adenocarcinoma. The positive expression of NM23-H1 was positively correlated with 5-year prognosis of patients (r = 0.887). The positive expression of CD44v6 was associated with 5-year prognosis Was negatively correlated (r = -0.784). [Conclusion] The expression of NM23-H1 and CD44v6 in cancer tissue can be used as an index to evaluate the prognosis of patients with N0 NSCLC.